Fused bicyclic imidazoles

1. A compound of formula (I)

wherein ring B and the imidazole to which it is fused form a ring system selected from

wherein

R1 is hydrogen, 1-4C-alkyl, halogen, amino, —SR2, trifluoromethyl, cyano, 3-7C-cycloalkyl, 2-4C-alkenyl, 2-4C-alkynyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, mono- or di-1-4C-alkylamino, mono- or di-1-4C-alkylaminocarbonyl, —C(NH)NH2, —C(O)NH2 or —C(O)OR10

R2 is hydrogen, 1-4C-alkyl or 3-7C-cycloalkyl,

R3 is hydrogen, 1-4C-alkyl or halogen,

R4 is phenyl substituted by R5, unsubstituted phenyl, thienyl, pyridinyl, thiazolyl or oxazolyl,

R5 is 1-4C-alkyl, halogen or 1-4C-alkoxy,

R6 is hydrogen or 1-4C-alkyl,

R7 is —W—Y,

W is a monocyclic 5-membered heteroarylene comprising 1 nitrogen atom and optionally 1 or 2 further heteroatoms independently selected from oxygen, nitrogen and sulphur,

and wherein the heteroarylene is optionally substituted by R8,

R8 is 1-4C-alkyl or 3-7C-cycloalkyl,

Y is phenyl or a monocyclic 5- or 6-membered heteroaryl comprising 1 nitrogen atom and optionally 1 or 2 further heteroatoms independently selected from oxygen, nitrogen, sulphur

and wherein the heteroaryl is optionally substituted by R9,

R9 is 1-4C-alkyl, 1-4C-alkoxy or halogen,

R10 is hydrogen or 1-4C-alkyl,

or a pharmaceutically acceptable salt, tautomer, or stereoisomer of said compound, or a pharmaceutically acceptable salt of said tautomer or said stereoisomer.

2. The compound according to claim 1 , wherein ring B and the imidazole to which it is fused form a ring system selected from

wherein

R1 is hydrogen, 1-4C-alkyl, halogen, amino, —SR2, trifluoromethyl, cyano, 3-7C-cycloalkyl, 2-4C-alkenyl, 2-4C-alkynyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, mono- or di-1-4C-alkylamino, mono- or di-1-4C-alkylaminocarbonyl, —C(NH)NH2, —C(O)NH2 or —C(O)OR10

R2 is hydrogen, 1-4C-alkyl or 3-7C-cycloalkyl,

R3 is hydrogen, 1-4C-alkyl or halogen,

R4 is phenyl substituted by R5, unsubstituted phenyl, thienyl, pyridinyl, oxazolyl or thiazolyl,

R5 is 1-4C-alkyl, halogen or 1-4C-alkoxy,

R6 is hydrogen or methyl,

R7 is —W—Y,

W is triazolylene, pyrazolylene, oxadiazolylene or imidazolylene,

each of which is optionally substituted by R8,

R8 is 1-4C-alkyl or 3-7C-cycloalkyl,

Y is phenyl, furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, each of which is optionally substituted by R9,

R9 is 1-4C-alkyl, 1-4C-alkoxy or halogen,

R10 is hydrogen or 1-4C-alkyl,

or a pharmaceutically acceptable salt, tautomer, or stereoisomer of said compound, or a pharmaceutically acceptable salt of said tautomer or said stereoisomer.

3. The compound according to claim 1 , wherein ring B and the imidazole to which it is fused form a ring system selected from

wherein

R1 is hydrogen, 1-4C-alkyl, halogen, amino, —SR2, trifluoromethyl, cyano, 3-7C-cycloalkyl, 2-4C-alkenyl, 2-4C-alkynyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, mono- or di-1-4C-alkylamino, mono- or di-1-4C-alkylaminocarbonyl, —C(NH)NH2, —C(O)NH2 or —C(O)OR10

R2 is hydrogen, 1-4C-alkyl or 3-7C-cycloalkyl,

R3 is hydrogen, 1-4C-alkyl or halogen,

R4 is phenyl substituted by R5, unsubstituted phenyl, thienyl, pyridinyl, oxazolyl or thiazolyl,

R5 is 1-4C-alkyl, halogen or 1-4C-alkoxy,

R6 is hydrogen or methyl,

R7 is —W—Y,

W is 1,2,4-triazolylene, pyrazolylene, 1,2,4-oxadiazolylene or imidazolylene,

Y is phenyl, furan-2-yl, thien-2-yl, pyrrol-2-yl, pyridin-4-yl, thiazol-2-yl, thiazol-4-yl, oxazol-2-yl, oxazol-4-yl, 1,3,4-thiadiazol-2-yl, 1,3,4-oxadiazol-2-yl, pyridin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl or pyridazin-3-yl, each of which is optionally substituted by R9,

R9 is 1-4C-alkyl, 1-4C-alkoxy or halogen,

R10 is hydrogen or 1-4C-alkyl,

or a pharmaceutically acceptable salt, tautomer, or stereoisomer of said compound, or a pharmaceutically acceptable salt of said tautomer or said stereoisomer.

4. The compound according to claim 1 , wherein ring B and the imidazole to which it is fused form a ring system selected from

wherein

R1 is hydrogen, 1-4C-alkyl, halogen, —SR2, amino, trifluoromethyl, cyano, 2-4C-alkenyl, 2-4C-alkynyl, 1-4C-alkoxy, mono- or di-1-4C-alkylamino, mono- or di-1-4C-alkylaminocarbonyl, —C(NH)NH2, —C(O)NH2 or —C(O)OR10

R2 is 1-4C-alkyl,

R3 is hydrogen or halogen,

R4 is phenyl substituted by R5, unsubstituted phenyl, thienyl, pyridinyl, oxazolyl or thiazolyl,

R6 is hydrogen,

R7 is —W—Y,

W is 1,2,4-triazolylene, pyrazolylene or 1,2,4-oxadiazolylene,

Y is phenyl, furan-2-yl, thien-2-yl, pyrrol-2-yl, pyridin-4-yl, thiazol-2-yl, pyridin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl or pyridazin-3-yl, each of which is optionally substituted by R9,

R9 is 1-4C-alkyl, 1-4C-alkoxy or halogen,

R10 is hydrogen or 1-4C-alkyl,

or a pharmaceutically acceptable salt, tautomer, or stereoisomer of said compound, or a pharmaceutically acceptable salt of said tautomer or said stereoisomer.

5. A compound according to claim 1 , selected from the group consisting of

3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-8-carbonitrile;

6-bromo-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

6-chloro-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

8-methyl-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-(4-fluorophenyl)-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

8-methoxy-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-(3-fluorophenyl)-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-(4-methoxyphenyl)-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-pyridin-4-yl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-3-(2-thienyl)imidazo[1,2-a]pyridine;

3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-7-carbonitrile;

3-phenyl-2-[4-({4-[5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-7-carbonitrile (2E)-but-2-enedioate 3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-8-carboximidamide;

3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-7-carboxamide;

3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-8-carboxamide;

6,8-Difluoro-3-phenyl-2-{4-[4-(5-pyridin-2-yl-4H-[1,2,4]triazol-3-yl)-piperidin-1-ylmethyl]-phenyl}-imides[1,2-a]pyridine;

3-phenyl-2-[4-({4-[5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-7-carbonitrile (2Z)-but-2-enedioate;

7-methyl-3-phenyl-2-[4-({4-[5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine;

6-bromo-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-7-carbonitrile;

7-chloro-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-phenyl-2-(4-{[4-(3-pyridin-4-yl-1H-1,2,4-triazol-5-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-7-carbonitrile;

3-phenyl-2-(4-{[4-(5-pyridin-4-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-phenyl-2-(4-{[4-(5-pyridin-4-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-8-carbonitrile;

2-[4-({4-[5-(6-methylpyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl) phenyl]-3-phenyl imidazo[1,2-a]pyridine-7-carbonitrile;

2-[4-({4-[5-(6-methylpyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]-3-phenyl imidazo[1,2-a]pyridine-8-carbonitrile;

2-[4-({4-[5-(6-methylpyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]-3-phenyl imidazo[1,2-a]pyridine;

7-methoxy-2-[4-({4-[5-(6-methylpyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]-3-phenylimidazo[1,2-a]pyridine;

2-[4-({4-[5-(5-methylpyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]-3-phenyl imidazo[1,2-a]pyridine-8-carbonitrile;

2-[4-({4-[5-(5-methylpyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]-3-phenyl imidazo[1,2-a]pyridine-7-carbonitrile;

2-[4-({4-[5-(5-chloropyridin-2-yl)-1H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl) phenyl]-3-phenyl imidazo[1,2-a]pyridine-8-carbonitrile;

3-phenyl-2-[4-({4-[5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl) phenyl]imidazo[1,2-a]pyridine-8-carbonitrile;

3-phenyl-2-[4-({4-[5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-7-carbonitrile;

3-phenyl-2-(4-{[4-(5-pyrimidin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-phenyl-2-[4-({4-[5-(1,3-thiazol-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine;

3-phenyl-2-[4-({4-[5-(1,3-thiazol-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-7-carbonitrile;

2-[4-({4-[5-(2-furyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]-3-phenylimidazo[1,2-a]pyridine-8-carbonitrile;

2-[4-({4-[5-(2-furyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]-3-phenylimidazo[1,2-a]pyridine;

2-[4-({4-[5-(2-furyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]-3-phenylimidazo[1,2-a]pyridine-7-carbonitrile;

3-phenyl-2-[4-({4-[5-(2-thienyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine;

3-phenyl-2-[4-({4-[5-(2-thienyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-8-carbonitrile;

3-phenyl-2-[4-({4-[5-(2-thienyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-7-carbonitrile;

7-chloro-3-phenyl-2-[4-({4-[5-(2-thienyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine;

3-phenyl-2-[4-({4-[5-(1H-pyrrol-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo1,2-a]pyridine-8-carbonitrile;

7-chloro-3-phenyl-2-[4-({4-[5-(1H-pyrrol-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine;

3-phenyl-2-[4-({4-[5-(1H-pyrrol-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-7-carbonitrile;

3-phenyl-2-(4-{[4-(3-pyridin-2-yl-1H-pyrazol-5-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

3-phenyl-2-(4-{[4-(5-pyridin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-7-carbonitrile;

3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-7-carbonitrile;

3-phenyl-2-(4-{[4-(5-phenyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl) imidazo[1,2-a]pyridine-8-carbonitrile;

3-phenyl-2-(4-{[4-(5-phenyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine-7-carbonitrile;

7-chloro-3-phenyl-2-(4-{[4-(5-phenyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)imidazo[1,2-a]pyridine;

methyl 3-phenyl-2-[4-({4-[5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-7-carboxylate;

3-phenyl-2-[4-({4-[5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}methyl)phenyl]imidazo[1,2-a]pyridine-7-carboxylic acid;

or a pharmaceutically acceptable salt, tautomer, or stereoisomer of said compound, or a pharmaceutically acceptable salt of said tautomer or said stereoisomer.

6. A pharmaceutical composition comprising at least one compound, tautomer of said compound or stereoisomer of said compound, or a pharmaceutically acceptable salt of said compound, tautomer or stereoisomer according to claim 1 , together with at least one pharmaceutically acceptable auxiliary.

7. A pharmaceutical composition according to claim 6 , further comprising one or more chemotherapeutic anti-cancer agents or target-specific anti-cancer agents.

8. A method for the treatment or amelioration of breast cancer comprising administering to a patient in need thereof a compound, or a tautomer of said compound, or a stereoisomer of said compound or a pharmaceutically acceptable salt of said compound, tautomer or stereoisomer according to claim 1 .

9. A method for the treatment or amelioration of breast cancer comprising administering to a patient in need thereof a compound, or a tautomer of said compound, or a stereoisomer of said compound or a pharmaceutically acceptable salt of said compound, tautomer or stereoisomer according to claim 2 .

10. A method for the treatment or amelioration of breast cancer comprising administering to a patient in need thereof a compound, or a tautomer of said compound, or a stereoisomer of said compound or a pharmaceutically acceptable salt of said compound, tautomer or stereoisomer according to claim 3 .

11. A method for the treatment or amelioration of breast cancer comprising administering to a patient in need thereof a compound, or a tautomer of said compound, or a stereoisomer of said compound or a pharmaceutically acceptable salt of said compound, tautomer or stereoisomer according to claim 4 .

12. A method for the treatment or amelioration of breast cancer comprising administering to a patient in need thereof a compound, or a tautomer of said compound, or a stereoisomer of said compound or a pharmaceutically acceptable salt of said compound, tautomer or stereoisomer according to claim 5 .